Delving into the Latest Updates on HRS-5817 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Obesity

Inactive Indication-

Originator Organization

Shanghai Tuojie Biotechnology Co., Ltd.

Active Organization

Fujian Suncadia Pharmaceuticals Co Ltd.

Shanghai Tuojie Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of HRS-5817. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of HRS-5817; To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of HRS-5817; To evaluate the immunogenicity characteristics of a single subcutaneous injection of HRS-5817.

Start Date-

Sponsor / Collaborator

Shanghai Tuojie Biotechnology Co., Ltd.

[+1]

NCT06934408

/ Not yet recruitingPhase 1

A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single ascending doses in adults who are affected by obesity.

Start Date01 Apr 2025

Sponsor / Collaborator

Fujian Suncadia Pharmaceuticals Co Ltd.

100 Clinical Results associated with HRS-5817

Login to view more data

100 Translational Medicine associated with HRS-5817

Login to view more data

100 Patents (Medical) associated with HRS-5817

Login to view more data

100 Deals associated with HRS-5817

Login to view more data